Please login to the form below
ceftazidime
This page shows the latest ceftazidime news and features for those working in and with pharma, biotech and healthcare.
Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought
Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle
Latest news
-
Pfizer launches new antibiotic Zavicefta in UK and Germany
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.
-
AZ slims down again with sale of antibiotics to Pfizer
The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
-
AZ gets EU green light for new antibiotic Zavicefta
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization.
-
Merck starts pivotal trials of new antibiotic combination
aeruginosa. AstraZeneca (AZ) recently secured CHMP backing in Europe for Zavicefta - which combines established cephalosporin antibiotic ceftazidime with new-generation beta lactamase inhibitor avibactam.
-
CHMP backs AZ's 'superbug' antibiotic product
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of Zavicefta (ceftazidime/avibactam), which combines an established antibiotic with a new drug designed to overcome bacterial resistance. ... In the US, Actavis (now operating
Pfizer launches new antibiotic Zavicefta in UK and Germany
AZ slims down again with sale of antibiotics to Pfizer
AZ gets EU green light for new antibiotic Zavicefta
Merck starts pivotal trials of new antibiotic combination
CHMP backs AZ's 'superbug' antibiotic product
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.
Deal Watch August 2016
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- $47.5m research centre to seek genetic insights into disease
- New data from Moderna supports COVID boosters
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
